Patents Examined by Stacy S. Brown
  • Patent number: 6673348
    Abstract: The present invention relates to methods and compositions for inducing an immune response in a subject, wherein the subject is administered an effective amount of a heat shock protein complexed to a hybrid antigen comprising an antigenic domain and a heat shock protein-binding domain. These methods and compositions may be used in the treatment of infectious diseases and cancers.
    Type: Grant
    Filed: February 27, 2001
    Date of Patent: January 6, 2004
    Assignee: Sloan-Kettering Institute for Cancer Research
    Inventors: James E. Rothman, F. Ulrich Hartl, Mee H. Hoe, Alan Houghton, Yoshizumi Takeuchi, Mark Mayhew
  • Patent number: 6660484
    Abstract: The present invention relates to methods and compositions for the direct detection of analytes using observable spectral changes in biopolymeric systems. In particular, the present invention allows for the direct colorimetric detection of analytes using color changes that occur in glycopolythiophene polymer systems in response to selective binding of analytes.
    Type: Grant
    Filed: December 11, 2000
    Date of Patent: December 9, 2003
    Assignee: Regents of the University of California
    Inventors: Deborah J. Charych, Myung-Gi Baek
  • Patent number: 6656679
    Abstract: The present invention relates to methods and compositions for inducing an immune response in a subject, wherein the subject is administered an effective amount of at least one heart shock protein in combination with one or more defined target antigens. These methods and compositions may be used in the treatment of infectious diseases and cancers.
    Type: Grant
    Filed: February 27, 2001
    Date of Patent: December 2, 2003
    Assignee: Sloan-Kettering Institute for Cancer Research
    Inventors: James E. Rothman, F. Ulrich Hartl, Mee H. Hoe, Alan Houghton, Yoshizumi Takeuchi, Mark Mayhew
  • Patent number: 6641812
    Abstract: The present invention relates to methods and compositions for inducing an immune response in a subject, wherein the subject is administered an effective amount of at least one heat shock protein in combination with one or more defined target antigens. These methods and compositions may be used in the treatment of infectious diseases and cancers.
    Type: Grant
    Filed: February 27, 2001
    Date of Patent: November 4, 2003
    Assignee: Sloan Kettering Institute for Cancer Research
    Inventors: James E. Rothman, F. Ulrich Hartl, Mee H. Hoe, Alan Houghton, Yoshizumi Takeuchi, Mark Mayhew
  • Patent number: 6635248
    Abstract: The present invention provides novel polypeptides which can effectively penetrate into cells thereby transporting a substance of interest into the cells.
    Type: Grant
    Filed: February 4, 2000
    Date of Patent: October 21, 2003
    Assignees: Institut Pasteur, Universite Pierre et Marie Curie
    Inventors: Therese Ternynck, Alexandre Avrameas, Gerard Buttin, Stratis Avrameas, Marie-Francoise Saron, Bruno Blondel, Therese Couderc, Susan Michelson, Donato Zipeto
  • Patent number: 6630316
    Abstract: A method for measuring the responses of sets or subsets of lymphocytes to mitogens or antigens in a sample is disclosed comprising incubating a population of cells with a mitogen or antigen, separating the desired subset of cells by means of the interaction of a specific binding reagent that is attached to the solid phase with a cell surface determinant that is present on the cell subset of interest, lysing the separated cells, and measuring an intracellular component that is increased if the cells have responded to the stimulus. The method provides a convenient, simple, and reliable method for measuring immune function in a variety of conditions.
    Type: Grant
    Filed: April 14, 1998
    Date of Patent: October 7, 2003
    Assignee: Cylex, Inc.
    Inventor: Marjorie L. Wier
  • Patent number: 6610308
    Abstract: The invention concerns an oil-in-water immunostimulant emulsion comprising an aqueous phase and an oil phase, characterised in that it further comprises an immunostimulant polynucleotide whereof at least part is covalently bound to at least a lipid molecule. The invention also concerns a vaccine composition comprising such an emulsion as immunoadjuvant.
    Type: Grant
    Filed: June 27, 2001
    Date of Patent: August 26, 2003
    Assignee: Aventis Pasteur S.A.
    Inventor: Jean Haensler
  • Patent number: 6605282
    Abstract: The subject invention pertains to novel methods and compositions for protecting cats from infection by a broad range of FIV strains using a multi-subtype FIV vaccine. Multi-subtype FIV vaccines comprising either cell free whole virus or cell lines infected with viruses are described. Methods for vaccinating cats with the subject vaccine compositions are also described. Cats vaccinated according to the methods and compositions of the subject invention exhibit protective humoral and cellular immune responses to FIV when challenged with homologous or heterologous strains of FIV. The subject invention also pertains to novel feline cell lines that are susceptible to infection by FIV and their methods of use.
    Type: Grant
    Filed: April 3, 2002
    Date of Patent: August 12, 2003
    Assignees: University of Florida Research Foundation, Inc., Regents of the University of California
    Inventor: Janet K. Yamamoto
  • Patent number: 6602705
    Abstract: The present invention relates to the efficient expression of HIV polypeptides in a variety of cell types, including, but not limited to, mammalian, insect, and plant cells. Synthetic expression cassettes encoding the HIV Gag-containing polypeptides are described, as are uses of the expression cassettes in applications including DNA immunization, generation of packaging cell lines, and production of Env-, tat- or Gag-containing proteins. The invention provides methods of producing Virus-Like Particles (VLPs), as well as, uses of the VLPs including, but not limited to, vehicles for the presentation of antigens and stimulation of immune response in subjects to whom the VLPs are administered.
    Type: Grant
    Filed: December 30, 1999
    Date of Patent: August 5, 2003
    Assignee: Chiron Corporation
    Inventors: Susan W. Barnett, Jan zur Megede, Catherine Greer, Mark Selby
  • Patent number: 6596478
    Abstract: The present invention comprises methods, devices and compositions for detection of endogenous retroviruses found in xenotransplant materials. The methods and compositions are suited for detection of endogenous type-C retroviruses and in particular, for porcine endogenous retrovirus, PERV.
    Type: Grant
    Filed: March 12, 2001
    Date of Patent: July 22, 2003
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Walid M. Heneine, William M. Switzer, Paul A. Sandstrom, Aprille L. Matthews, Thomas M. Folks
  • Patent number: 6592869
    Abstract: The present invention relates to a stable compacted, compressed or hard tableted injectable composition, including a vaccine composition comprising at least one freeze dried antigenic component and a dissolution aid. A package containing the above injectable composition and method to facilitate immunizing a subject against a disease comprising the steps of first dissolving the compacted, compressed or hard tableted vaccine composition in a package with a diluent to form a vaccine solution, and administering the resulting vaccine solution in an amount effective for immunizing is also provided.
    Type: Grant
    Filed: February 28, 2001
    Date of Patent: July 15, 2003
    Assignee: Teva Pharmaceutical Industries, Ltd.
    Inventors: Gilad Gallili, Norbert Frydman
  • Patent number: 6589748
    Abstract: A method is disclosed for diagnosing early stage of a disease in which an intact protein found in urine is an indicator of the disease. The method includes assaying urine sample to detect the presence of modified protein using either immunological or non-immunological technique. Methods for preventing and treating the disease are also disclosed.
    Type: Grant
    Filed: June 28, 2001
    Date of Patent: July 8, 2003
    Assignee: Monash University
    Inventor: Wayne D. Comper
  • Patent number: 6589529
    Abstract: The present invention is directed to the generation and use of recombinant rotavirus fusion proteins as immunogens to produce a protective immune response from immunized individuals. In one embodiment, the present invention contemplates a recombinant rotavirus fusion protein vaccine composition comprising a rotavirus subunit protein or immunogenic fragment thereof, and an adjuvant in combination with the recombinant rotavirus subunit fusion protein. In one aspect of this embodiment, the recombinant rotavirus fusion protein comprises a rotavirus subunit protein and a fusion partner protein in genetic association with the rotavirus subunit protein, wherein the fusion partner protein does not interfere with expression and immunogenicity of the rotavirus subunit protein, the fusion partner protein prevents complex formation by the rotavirus subunit protein, and the fusion partner protein facilitates purification of the recombinant rotavirus fusion protein.
    Type: Grant
    Filed: October 29, 1999
    Date of Patent: July 8, 2003
    Assignee: Children's Hospital Medical Center
    Inventors: Anthony Choi, Richard L. Ward
  • Patent number: 6582901
    Abstract: The present invention concerns a method of testing the viral susceptibility of a compound. It includes the steps of mixing subject cells infected with a virus with target cells. The target cells of the compound include a marker. Another step includes stimulating viral production. The mixture is then subjected to at least one antiviral compound. Viral production in the target cells is then detected.
    Type: Grant
    Filed: April 26, 2001
    Date of Patent: June 24, 2003
    Inventor: Bruce K. Patterson
  • Patent number: 6576757
    Abstract: This invention is directed to antigen library immunization, which provides methods for obtaining antigens having improved properties for therapeutic and other uses. The methods are useful for obtaining improved antigens that can induce an immune response against pathogens, cancer, and other conditions, as well as antigens that are effective in modulating allergy, inflammatory and autoimmune diseases.
    Type: Grant
    Filed: November 28, 2000
    Date of Patent: June 10, 2003
    Assignee: Maxygen, Inc.
    Inventors: Juha Punnonen, Steven H. Bass, Robert Gerald Whalen, Russell Howard, Willem P. C. Stemmer
  • Patent number: 6573081
    Abstract: Methods for growing circoviruses, in particular porcine circoviruses, which are obtained from an infected cell culture after one or more passages in cultures of porcine, bovine or human cells are described. When the porcine circoviruses grow, a cytopathogenic effect occurs in the cell culture.
    Type: Grant
    Filed: September 7, 2001
    Date of Patent: June 3, 2003
    Assignee: Aventis Behring GmbH
    Inventors: Dieter Bernhardt, Thomas Weimer, Albrecht Groener
  • Patent number: 6569435
    Abstract: This invention is directed to antigen library immunization, which provides methods for obtaining antigens having improved properties for therapeutic and other uses. The methods are useful for obtaining improved antigens that can induce an immune response against pathogens, cancer, and other conditions, as well as antigens that are effective in modulating allergy, inflammatory and autoimmune diseases.
    Type: Grant
    Filed: November 28, 2000
    Date of Patent: May 27, 2003
    Assignee: Maxygen, Inc.
    Inventors: Juha Punnonen, Steven H. Bass, Robert Gerald Whalen, Russell Howard, Willem P. C. Stemmer
  • Patent number: 6569616
    Abstract: A method of designing a new anti-CMV drug is disclosed. In one embodiment, the invention comprises (a) analyzing the binding of glycoprotein O to a glycoprotein O receptor and (b) designing a candidate drug that would competitively interfere with glycoprotein O binding to glycoprotein O receptor and (c) showing that the candidate drug competitively inhibits glycoprotein O binding to glycoprotein O receptor. A method of screening anti-CMV drugs, a vaccine effective to diminish CMV infection, and a method of diminishing CMV infection are also disclosed.
    Type: Grant
    Filed: July 28, 2000
    Date of Patent: May 27, 2003
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Teresa Compton, Mary T. Huber
  • Patent number: 6569430
    Abstract: An antibody is produced, which will bind effectively with the antigen Campath-1, and which has at least one complementarity determining region of rat origin, as identified in FIG. 2, which may be combined with a range of different foreign variable domain framework regions as desired, including framework regions of human origin.
    Type: Grant
    Filed: March 21, 1995
    Date of Patent: May 27, 2003
    Assignee: BTG International Limited
    Inventors: Herman Waldmann, Michael R. Clark, Gregory P. Winter, Lutz Riechmann
  • Patent number: 6558948
    Abstract: The invention relates to a permanent amniocytic cell line comprising at least one nucleic acid which brings about expression of the gene products of the adenovirus E1A and E1B regions. The present invention further relates to the production of a permanent amniocytic cell line and to its use for producing gene transfer vectors and/or adenovirus mutants. Further aspects are the use of amniocytes and of the adenoviral gene products of the E1A and E1B regions for producing permanent amniocytic cell lines.
    Type: Grant
    Filed: November 16, 2000
    Date of Patent: May 6, 2003
    Inventors: Stefan Kochanek, Gudrun Schiedner